インターフェロンアルファ-2b、インターフェロンアルファ2b
WordNet
- an antiviral protein produced by cells that have been invaded by a virus; inhibits replication of the virus
PrepTutorEJDIC
- インターフェロン(ウイルス増殖抑制物質)
- インターフェロン (virusの増殖を抑制する)
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/03/03 10:19:45」(JST)
wiki en
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. Management of recurrent or persistent non-muscle invasive bladder cancer
- 2. 再発髄膜腫の全身治療 systemic treatment of recurrent meningioma
- 3. 癌免疫療法の原則 principles of cancer immunotherapy
- 4. 悪性黒色腫に対する補助免疫療法 adjuvant immunotherapy for melanoma
- 5. Treatment regimens for chronic hepatitis C virus genotypes 2 and 3 infection in adults
English Journal
- Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2.
- Ma C, Armstrong AW.Author information Department of Dermatology, University of California Davis , Sacramento, CA , USA.AbstractBackground: Current immunomodulatory agents for stage III and IV melanoma exert different mechanisms of action that manifest in distinct adverse events. Objective: This systematic review aims to synthesize safety data from clinical trials on ipilimumab, vemurafenib, interferon (IFN) alfa-2b, dacarbazine and interleukin (IL)-2 to elucidate the severe adverse events associated with each melanoma therapy. Methods: Through a systematic search using MEDLINE, EMBASE and the Cochrane Central Register between January 1, 2010 and June 1, 2012, we identified 32 clinical trials with 5802 subjects that met the inclusion criteria. Results:Ipilimumab was associated with immune-mediated diarrhea and colitis, with an incidence rate of 0.0017 cases per 100 person-years. Patients receiving vemurafenib developed keratoacanthomas and cutaneous squamous cell carcinoma at an incidence rate of 0.0025 cases per 100 person-years. Treatment with IFN alfa-2b precipitated depression at an incidence rate of 0.0002 cases per 100 person-years. Dacarbazine was associated with respiratory toxicity and dyspnea, with incidence rates of 0.0001 and 0.00008 cases per 100 person-years, respectively. IL-2 treatment induced vascular leak syndrome (VLS), with symptoms of hypotension and oliguria, was observed at incidence rates of 0.17 and 0.15 cases per 100 person-years, respectively. Findings may serve as a foundation for future research in this area and guide clinical recommendations.
- The Journal of dermatological treatment.J Dermatolog Treat.2014 Oct;25(5):401-8. doi: 10.3109/09546634.2013.813897. Epub 2013 Jul 3.
- Background: Current immunomodulatory agents for stage III and IV melanoma exert different mechanisms of action that manifest in distinct adverse events. Objective: This systematic review aims to synthesize safety data from clinical trials on ipilimumab, vemurafenib, interferon (IFN) alfa-2b, dacarba
- PMID 23763243
- Conjunctival intraepithelial neoplasia. Interferon as a rescue therapy after failure of mitomycin C.
- de la Cruz Aguiló RI1, Duch-Samper A2, Hernández Pérez D2, Marí Cotino J2.Author information 1Servicio de Oftalmología, Hospital Clínico Universitario de Valencia, Valencia, España. Electronic address: delacruzaguilo@gmail.com.2Servicio de Oftalmología, Hospital Clínico Universitario de Valencia, Valencia, España.AbstractCLINICAL CASE: The case of a 60 year-old male with a conjunctival lesion diagnosed as conjunctival intraepithelial neoplasia (CIN), who was treated with mitomycin-C for 3 weeks with minimal improvement. The therapy was change to interferon 2B. Six month later, and after a complete remission of the lesion, the treatment was suspended, with no signs of relapse.
- Archivos de la Sociedad Espanola de Oftalmologia.Arch Soc Esp Oftalmol.2013 Dec 27. pii: S0365-6691(13)00387-0. doi: 10.1016/j.oftal.2013.11.009. [Epub ahead of print]
- CLINICAL CASE: The case of a 60 year-old male with a conjunctival lesion diagnosed as conjunctival intraepithelial neoplasia (CIN), who was treated with mitomycin-C for 3 weeks with minimal improvement. The therapy was change to interferon 2B. Six month later, and after a complete remission of the l
- PMID 24377953
- Successful telaprevir treatment in combination of cyclosporine against recurrence of hepatitis C in the Japanese liver transplant patients.
- Kikuchi M, Okuda Y, Ueda Y, Nishioka Y, Uesugi M, Hashimoto E, Takahashi T, Kawai T, Hashi S, Shinke H, Omura T, Yonezawa A, Ito T, Fujimoto Y, Kaido T, Chiba T, Uemoto S, Matsubara K, Masuda S.Author information Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Faculty of Medicine.AbstractTelaprevir (TVR) is a protease inhibitor used in combination with pegylated interferon alfa-2b and ribavirin for hepatitis C, and TVR strongly inhibits cytochrome P450 3A4 (CYP3A4) and CYP3A5. We reported successful TVR treatment of liver transplant patients with recurrence of hepatitis C during receiving immunosuppressive therapy. Before initiation of triple therapy, all patients switched from tacrolimus to cyclosporine, which has a lower inhibitory effect on CYP3A4 and CYP3A5 than tacrolimus. To avoid graft failure, we measured the cyclosporine blood concentrations at 0, 2, and 6 h after administration to maintain the target level (150-200 ng/mL) within 1 week after initiation of TVR and adjusted the dose of cyclosporine. The dose of cyclosporine was decreased 0.24-0.40 fold in all patients after initiation of TVR treatment. In 3 patients, the dose of TVR was decreased two-thirds of starting dose because of adverse effects, including anorexia and skin rash. However, the HCV RNA level rapidly decreased to undetectable levels within 1 month. Furthermore, all patients completed the TVR therapy in 12 weeks and did not experience liver graft rejection. In addition, we found the rapid elimination of inhibitory effect of TVR on the disposition of cyclospirne in the all four cases and therefore, rapid increase in the dosage of cyclosporine would be required immediately after the end of TVR administration. These results suggest that frequent measurement of cyclosporine levels was important for successful TVR triple therapy and prevention of rejection.
- Biological & pharmaceutical bulletin.Biol Pharm Bull.2013 Dec 26. [Epub ahead of print]
- Telaprevir (TVR) is a protease inhibitor used in combination with pegylated interferon alfa-2b and ribavirin for hepatitis C, and TVR strongly inhibits cytochrome P450 3A4 (CYP3A4) and CYP3A5. We reported successful TVR treatment of liver transplant patients with recurrence of hepatitis C during rec
- PMID 24369269
Japanese Journal
- A Chronic Subdural Hematoma in a Patient Receiving Combination Therapy with Pegylated Interferon Alfa-2b and Ribavirin for Chronic Hepatitis C
- Goto Takashi,Ohshima Shigetoshi,Miura Kouichi,Shibuya Tomomi,Sato Wataru,Dohmen Takahiro,Kamada Kentaro,Kanata Ryo,Sakai Toshitaka,Chiba Mitsuru,Sugimoto Yuko,Minami Shinichiro,Ohnishi Hirohide
- Internal Medicine 52(18), 2057-2060, 2013
- … He was treated with pegylated interferon and ribavirin. … Treatment with pegylated interferon and ribavirin was discontinued. …
- NAID 130003365824
- C型代償性肝硬変を対象としたペグインターフェロン アルファ-2bとリバビリン併用投与試験
- 熊田 博光,岡上 武
- 肝臓 53(12), 803-813, 2012-12
- NAID 40019530469
- 難治性C型肝炎に対するPeg-IFN/Ribavirin併用療法の適応と限界 (特集 C型肝炎治療の新たな展開)
- 平松 直樹,小瀬 嗣子,竹原 徹郎
- 消化器内科 54(4), 469-477, 2012-04
- NAID 40019320977
Related Links
- Interferon alfa-2b injection may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away: bruising, bleeding, pain, redness, swelling, or irritation in the place you injected interferon alfa-2b muscle pain
- Peginterferon alfa-2b may cause or worsen the following conditions that may be serious or cause death: infections; mental illness including depression, mood and behavior problems, or thoughts of hurting or killing yourself or others ...
Related Pictures
★リンクテーブル★
| リンク元 | 「インターフェロンアルファ-2b」 |
| 拡張検索 | 「peginterferon alfa-2b」 |
| 関連記事 | 「interferon alfa」「alfa」「interferon」 |
「インターフェロンアルファ-2b」
- 英
- interferon alfa-2b
- 関
- インターフェロンアルファ2b
「peginterferon alfa-2b」
ペグインターフェロンアルファ-2b、ペグインターフェロンアルファ2b
「interferon alfa」
「alfa」
- 関
- alpha